BeiGene (BGNE) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $41. Maxim Group advised their investors in a research report released on Sep 22, 2016.
On the company’s financial health, BeiGene reported $-0.73 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.68. The company had revenue of $.40 million for the quarter, compared to analysts expectations of $2.08 million. The company’s revenue was down -71.4 % compared to the same quarter last year.
In a different news, on Feb 9, 2016, Howard Liang (CFO) purchased 65,000 shares at $1.85 per share price. According to the SEC, on Feb 9, 2016, Ruirong Yuan (Chief Medical Officer) purchased 130,000 shares at $1.85 per share price.